Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PREMIER BIOTECH LABS, LLC

NPI: 1700280971 · MINNEAPOLIS, MN 55414 · Clinical Medical Laboratory · NPI assigned 10/17/2014

$41.43M
Total Medicaid Paid
784,980
Total Claims
443,877
Beneficiaries
37
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialMICHALIK, MATTHEW (CFO)
NPI Enumeration Date10/17/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 31,523 $1.24M
2019 126,147 $7.34M
2020 112,948 $6.91M
2021 152,544 $6.89M
2022 123,127 $6.52M
2023 135,190 $6.81M
2024 103,501 $5.71M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 366,254 213,538 $13.15M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 163,346 109,233 $11.46M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 72,155 23,448 $8.21M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 32,787 11,901 $4.25M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 43,561 21,822 $4.01M
80363 2,439 1,545 $100K
80346 8,524 4,961 $48K
80362 5,090 3,149 $18K
80348 6,716 4,111 $17K
80360 6,472 4,149 $13K
80357 5,933 3,458 $13K
80321 3,580 2,119 $13K
80323 5,226 3,093 $13K
80345 2,646 1,527 $12K
80173 1,223 490 $10K
80349 5,118 3,192 $10K
80354 4,203 2,534 $9K
80324 3,996 2,386 $9K
80368 3,459 2,087 $8K
80365 3,502 2,039 $7K
80361 3,527 2,061 $7K
80358 2,966 1,798 $6K
80353 3,720 2,191 $6K
80369 2,894 1,758 $6K
80356 2,835 1,679 $5K
83992 2,624 1,520 $4K
80372 2,756 1,600 $4K
80373 2,796 1,667 $4K
80366 3,224 2,090 $1K
80335 2,058 1,257 $1K
80367 2,191 1,207 $448.29
80355 5,954 3,999 $108.95
80338 327 83 $0.00
80336 287 56 $0.00
80375 12 12 $0.00
80359 292 61 $0.00
80333 287 56 $0.00